URMC / Research / Clinical Trials / Study Details CMEL20008, Victor, EA6174, Merkel Cell Carcinoma, Pembrolizumab Basic Study Information Purpose:This phase III trial studies how well pembrolizumab works compared to standard of care observation in treating patients with stage I-III Merkel cell cancer that has been completely removed by surgery (resected). Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Location: University of RochesterLead Researcher (Principal Investigator) Lead Researcher: Adrienne Victor Study Contact InformationStudy Coordinator: Tina BowdishPhone: +1 585-275-9475Email: tina_bowdish@urmc.rochester.edu Additional Study Details URMC / Wilmot Cancer Institute /Research / Clinical Trials / Study Details Trial Not Found The study you are looking for is not active at this time. Return to Search